Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTH2: Preemptive Acyclovir in Mechanically Ventilated ICU Patients With HSV Reactivation
2023-505510-26-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aciclovir in herpes simplex (HSV), respiratory failure and critical illness (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Day-60 all-cause mortality post randomization. Planned start Jan 2024; status: authorised.
02
Drugs
aciclovir
03
Conditions
herpes simplex (HSV)respiratory failurecritical illness
Beyond the preview
Go deeper on 2023-505510-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505510-26-00.